drugset / Trial / NCT05693558
NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia
NaSingle-groupOpen-labelTreatment
Summary
A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.
Timeline
- Start
- 2022-11-24
- Primary completion
- 2025-01
- Completion
- 2026-01
Publications
- Background Paley D. Congenital pseudarthrosis of the tibia: biological and biomechanical considerations to achieve union and prevent refracture. J Child Orthop. 2019 Apr 1;13(2):120-133. doi: 10.1302/1863-2548.13.180147.
- Background Dufrane D. Impact of Age on Human Adipose Stem Cells for Bone Tissue Engineering. Cell Transplant. 2017 Sep;26(9):1496-1504. doi: 10.1177/0963689717721203.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NVD003 | Cell therapy | — | — |